Arrowhead Pharmaceuticals and Vivo Capital Launch Joint Venture Aimed at Greater China Market Arrowhead Pharmaceuticals, a US company focused on therapies triggering the RNA interference (RNAi), and Vivo Capital, a global healthcare investment firm with offices in Palo Alto, CA, and in China, have formed a new joint venture, Visirna…..
New data-driven approach to help reduce drug costs and treat diseases A new data-driven mechanistic approach that predicts cell types within tissue will help to reduce drug costs and treat diseases that were difficult to develop drugs for, according to a West Virginia University scientist. [caption id="attachment_10508" align="aligncenter" width="700"] WVU…..
TreeFrog Therapeutics opens technological hub in Kobe, Japan, to drive partnerships opportunities in the field of iPSC-derived cell therapies TreeFrog Therapeutics, a French-based biotech company aimed at making safer, more efficient and more affordable cell therapies based on induced pluripotent stem cells (iPSCs), announced the incorporation of its Japanese subsidiary…..
Novasep, a major CDMO focused on complex small molecules and antibody-drug conjugates (ADCs), and PharmaZell, a leading supplier of highly resilient and specialty APIs, have just closed their merger, following exclusive negotiations initiated in September 2021. This strategic merger creates a technology driven, leading Franco-German CDMO and API manufacturer. Novasep’s…..
Novartis expands Zolgensma® manufacturing capacity with approval of multi-product North Carolina facility The FDA has granted commercial licensure approval for Novartis' Durham, N.C. site, a multi-product gene therapy manufacturing facility. This approval allows the state-of-the-art, 170,000 square-foot facility to make, test and release commercial Zolgensma®, as well as produce…..
Experimental siRNA therapy SLN360 shows promise for previously untreatable heart disease risk factor
Experimental siRNA therapy SLN360 shows promise for previously untreatable heart disease risk factor While there are effective therapies to reduce the risk of heart disease by lowering low-density lipoprotein (LDL), or “bad” cholesterol, and other lipids, to date there are no approved treatments to lower lipoprotein(a), a lesser-known driver of…..
Microbiota medicine: towards clinical revolution 21 high-level authors and members of the International Society of Microbiota, coming from 8 countries and more than 10 reputable institutions published a new strategic report titled “Microbiota medicine: towards clinical revolution”. Published in the Journal of Translational Medicine, this stunning review confirms that microbiota…..
